BioSpace News Archive

- Papilocare® demonstrates efficacy of in healing cervical lesions 6 months after treatment in 88% of patients affected by high-risk HPV - Papilocare® cleared HPV lesions in 63% of patients with high-risk HPV compared with 40% in the control group - BioVaxys has right of refusal for US marketing of Papilocare®

- Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge -

- NT-300 reduced progression to severe COVID-19 disease by 85% - Romark is working with FDA and plans to seek Emergency Use Authorization in the U.S.

Ardelyx, Inc. today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has initiated four Phase 3 clinical studies in Japan evaluating tenapanor for hyperphosphatemia.

A compact, ergonomic benchtop unit designed to fit in almost any laboratory or production line setup, the LT-Pro Leak Tester is suitable for pharmaceutical, food and beverage, and personal care applications.

Noxopharm Files Septic Shock Treatment Patent for Veyonda ® New indication doubles the commercial opportunity

Spectrum Solutions , LLC today announced David J. Vigerust, MS., PhD. has been named the company’s new Chief Scientific Officer. Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.

ProtoKinetix, Incorporated (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP®.

- Marketing Authorization Application (MAA) Submission in Europe Planned for Q4 2021 - Phase 3 Trial in Europe and U.S. Expected to Begin in Q3 2021 to Support Regulatory Submissions

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2021 before the market opens on Wednesday, May 5, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.